What this trial studies
Within the context of the proposed research study, the effect of soy isoflavonoid supplements on the quality of life and coagulation of menopausal women. It has been observed that menopause, as a physiological process, is associated with alterations in the physical, mental and sexual quality of life, making the use of hormone replacement therapy necessary; however, hormone therapy is associated with hypercoagulability, since it has been seen that women have higher levels of thrombogenic microvesicles such as: platelets with a greater probability of causing blood clotting were more likely to present a greater amount of white matter hyperintensities, which appear in the MRI scan.
Conditions in scope
- Menopause
- Menopausal Women
- Soy Isoflavone Effect
- Quality of Life
Interventions
- Soy isoflavone supplement (Dietary Supplement) — 2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.
- Control (placebo) group (Other) — 2 placebo capsules containing a multivitamin compound.
Who can join
Women only · Ages 45 Years to 65 Years · Accepts healthy volunteers.
Inclusion criteria
- Submission of a signed and dated informed consent form.
- Declared willingness to comply with all study procedures and availability for the duration of the study.
- Can read and write
- Female, age 45 to 65 years
- Female with more than 1 year of amenorrhea.
- No hormone replacement therapy or herbal medications in the 6 months prior to the investigation.
- Ability to take oral medication and willing to comply with the \<study intervention regimen.
- Agreement to comply with Lifestyle Considerations for the duration of the study.
Exclusion criteria
- Patient does not sign informed consent
- Patient does not wish to participate
- History of thrombo embolism
- History of cardiovascular disease
- Presence of estrogen-dependent neoplasm
- Presence of abnormal genital bleeding
- Uncontrolled metabolic diseases
- Smoking and drinking habits
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Tegucigalpa | FM | Hospital Escuela | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2025-02-01
- Primary completion: 2025-07-31
- Last update posted: 2025-08-28
- First posted: 2025-01-06
Sponsor & contact
Lead sponsor: Universidad Nacional Autonoma de Honduras (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- MENCAV (One month from the first intervention until 6 months)
Change in MENCAV questionnaire scores, with 37 items likert type scale, the lowest point is zero and the maximun is 259 points
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06759350 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.